• Maria Halasz appointed as new CEO of Genetic Signatures
• Over 20 years of senior executive, board and capital markets experience
• Proven ability to translate innovation into shareholder value

Genetic Signatures Limited [ASX:GSS] ('GSS' or the 'Company'), a global molecular diagnostics company, today announces that its Board of Directors has appointed Maria Halasz as Chief Executive Officer, based in Sydney, Australia. Ms Halasz brings over 20 years of senior executive, board and capital markets experience, with deep expertise in commercialization, corporate strategy, corporate development, investor engagement and building international markets, particularly within the life sciences, healthcare and highly regulated sectors. Ms Halasz has substantial experience leading and engaging with public-market investors, having served for 14 years as Chief Executive Officer and Managing Director of Anagenics Limited (formerly Cellmid Limited, ASX: AN1). During her tenure, she led multiple capital raisings, asset acquisitions, restructures and licensing transactions, working closely with institutional and retail investors. Ms Halasz is a Graduate of the Australian Institute of Company Directors (GAICD) and currently serves as Non-Executive Director of the Garvan Research Foundation. Caroline Waldron, Chair of Genetic Signatures commented: 'Maria brings a rare combination of leadership, a scientific background, capital markets credibility and deep commercialization experience, all of which are relevant for the next stage of Genetic Signatures' growth. Her proven ability to translate innovation into shareholder value, engage effectively with customers, and build sustainable international businesses will be a significant asset to GSS as we execute our growth strategy.' Maria Halasz, incoming CEO of Genetic Signatures said: 'Genetic Signatures has built an exceptional molecular diagnostics platform with growing international relevance. I am excited to bring my experience in commercialization, strategy and global market development to help the GSS team scale the business, expand its international footprint and translate its innovation into meaningful commercial outcomes.'